Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-1780 tablets and will conduct clinical trials in the near future.

HRS-1780 tablets are salicocorticoid receptor antagonists (MRA), clinically intended to treat uncontrolled or refractory hypertension. MRA has been recommended as the drug of choice in addition to standard treatment to manage refractory hypertension. A similar selective nonsteroidal MRA ethalidone was marketed in Japan for the treatment of hypertensive patients, and no similar products have been sold domestically. Currently, the project has clinical trials for the treatment of chronic kidney disease and primary hyperaldosteronism under simultaneous development and has progressed to Phase II/III. Up to now, the total R&D investment for HRS-1780 film-related projects is approximately RMB 100.4 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.